Literature DB >> 26896118

Development of a New Adult Sickle Cell Disease Center Within an Academic Cancer Center: Impact on Hospital Utilization Patterns and Care Quality.

Biree Andemariam1, Sasia Jones2.   

Abstract

BACKGROUND: A national shortage of specialized centers with expertise in the management of adults with sickle cell disease (SCD) remains a concerning public health disparity. Yet, there is an abundance of cancer centers whose operational infrastructure is not only suited to the treatment of the oncology patient, but also can provide medical and procedural care essential to the management of the patient with SCD. Our adult SCD center was formally embedded within an academic hospital-based cancer center in 2009. An evaluation of the impact of this new center has been performed.
METHODS: A retrospective chart review was conducted of all SCD encounters occurring 5 years pre- and post-SCD center establishment. Demographic, clinical, as well as hospital utilization and care quality data were compared.
RESULTS: The SCD population grew from 22 to 165 patients. Following establishment of the SCD center, patients experienced greater average annual outpatient preventative visits for chronic disease management (1 vs. 4.1) and fewer average hospitalizations yearly (2.4 vs. 1). There was a decrease in hospitalization rates for management of acute pain (50 vs. 23 %), average hospitalization length of stay (12 vs. 6 days), and the proportion of hospital discharges resulting in readmission within 30 days (60 vs. 40 %). Hydroxyurea use among eligible patients increased from 30 to 90 %.
CONCLUSION: Findings suggest that embedding adult SCD centers within existing cancer centers can positively impact patterns of health care utilization and improve the quality of care.

Entities:  

Keywords:  Cancer center; Quality; Sickle cell disease; Utilization

Mesh:

Year:  2015        PMID: 26896118     DOI: 10.1007/s40615-015-0142-7

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


  22 in total

1.  Hydroxyurea and anagrelide combination therapy in patients with chronic myeloproliferative diseases resistant or intolerant to monotherapy.

Authors:  A Christoforidou; D Pantelidou; A Anastasiadis; A Goutzouvelidis; D Margaritis; I Kotsianidis; E Spanoudakis; V Kaloutsi; G Bourikas; C Tsatalas
Journal:  Acta Haematol       Date:  2009-01-08       Impact factor: 2.195

2.  National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease.

Authors:  Otis W Brawley; Llewellyn J Cornelius; Linda R Edwards; Vanessa Northington Gamble; Bettye L Green; Charles Inturrisi; Andra H James; Danielle Laraque; Magda Mendez; Carolyn J Montoya; Brad H Pollock; Lawrence Robinson; Aaron P Scholnik; Melissa Schori
Journal:  Ann Intern Med       Date:  2008-05-05       Impact factor: 25.391

3.  Incidence and natural history of proliferative sickle cell retinopathy: observations from a cohort study.

Authors:  Susan M Downes; Ian R Hambleton; Elaine L Chuang; Noemi Lois; Graham R Serjeant; Alan C Bird
Journal:  Ophthalmology       Date:  2005-09-19       Impact factor: 12.079

4.  Caring for the adult with sickle cell disease: results of a multidisciplinary pilot program.

Authors:  Nicole Artz; Chad Whelan; Sharon Feehan
Journal:  J Natl Med Assoc       Date:  2010-11       Impact factor: 1.798

5.  Is the medical home for adult patients with sickle cell disease a reality or an illusion?

Authors:  Samir K Ballas; Elliott P Vichinsky
Journal:  Hemoglobin       Date:  2015-03-25       Impact factor: 0.849

6.  The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up.

Authors:  Martin H Steinberg; William F McCarthy; Oswaldo Castro; Samir K Ballas; F Danny Armstrong; Wally Smith; Kenneth Ataga; Paul Swerdlow; Abdullah Kutlar; Laura DeCastro; Myron A Waclawiw
Journal:  Am J Hematol       Date:  2010-06       Impact factor: 10.047

Review 7.  Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members.

Authors:  Barbara P Yawn; George R Buchanan; Araba N Afenyi-Annan; Samir K Ballas; Kathryn L Hassell; Andra H James; Lanetta Jordan; Sophie M Lanzkron; Richard Lottenberg; William J Savage; Paula J Tanabe; Russell E Ware; M Hassan Murad; Jonathan C Goldsmith; Eduardo Ortiz; Robinson Fulwood; Ann Horton; Joylene John-Sowah
Journal:  JAMA       Date:  2014-09-10       Impact factor: 56.272

8.  Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease.

Authors:  Louis-Philippe Laurin; Patrick H Nachman; Payal C Desai; Kenneth I Ataga; Vimal K Derebail
Journal:  Nephrol Dial Transplant       Date:  2013-09-30       Impact factor: 5.992

9.  Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

Authors:  Michel Delforge; Dominik Selleslag; Yves Beguin; Agnès Triffet; Philippe Mineur; Koen Theunissen; Carlos Graux; Fabienne Trullemans; Dominique Boulet; Koen Van Eygen; Lucien Noens; Steven Van Steenweghen; Jan Lemmens; Pascal Pierre; Randal D'hondt; Augustin Ferrant; Dries Deeren; Ann Van De Velde; Wim Wynendaele; Marc André; Robrecht De Bock; André Efira; Dimitri Breems; Anne Deweweire; Kurt Geldhof; Wim Pluymers; Amanda Harrington; Karen MacDonald; Ivo Abraham; Christophe Ravoet
Journal:  Leuk Res       Date:  2014-02-14       Impact factor: 3.156

10.  Blood use in the ambulatory setting among elderly in the United States.

Authors:  Mikhail Menis; Dale R Burwen; Leslie Holness; Steven A Anderson
Journal:  Transfusion       Date:  2009-02-27       Impact factor: 3.157

View more
  1 in total

1.  Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.

Authors:  Julie Kanter; Wally R Smith; Payal C Desai; Marsha Treadwell; Biree Andemariam; Jane Little; Diane Nugent; Susan Claster; Deepa G Manwani; Judith Baker; John J Strouse; Ifeyinwa Osunkwo; Rosalyn W Stewart; Allison King; Lisa M Shook; John D Roberts; Sophie Lanzkron
Journal:  Blood Adv       Date:  2020-08-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.